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ABSTRACT: The first examples of iminosugar-type 2-deoxy(thio)glycoside mimetics are reported. The key step is the activation of 
a bicyclic iminoglycal carbamate to generate a highly reactive acyliminium cation. Cerium(IV) ammonium nitrate efficiently pro-
moted the formation of 2-deoxy S-glycosides in the presence of thiols, probably by in situ generation of catalytic HNO3, with complete 
α-stereoselectivity. Cooperative phosphoric acid/Schreiner's thiourea organocatalysis proved better suited for generating 2-deoxy O-
glycosides, significantly broadening the scope of the approach. 
INTRODUCTION 
The synthesis of 2-deoxyglycosides has drawn considerable 
attention from carbohydrate, organic and medicinal chemists 
since these motifs are present in a broad variety of natural prod-
ucts and clinically relevant agents displaying antitumor, antimi-
crobial or anti-HIV activities, among others.1-3 The incorpora-
tion of 2-deoxyglycosides and their analogs in drug discovery 
is hindered, however, by the difficulties associated with their 
stereoselective preparation and the insufficient metabolic sta-
bility of the glycosides. The absence of a neighboring partici-
pant group at the C-2 position in 2-deoxyglycosyl donors, such 
as in a glycal (1,2-unsaturated sugar), to bias the stereochemical 
outcome, makes notoriously challenging the control of the ano-
meric configuration in the glycosylation reaction. In addition, 
the resulting C-2 unsubstituted products are more susceptible to 
acid-catalyzed hydrolysis and henceforth are more difficult to 
handle. The total or partial cleavage of the saccharide moieties 
by the action of glycosidases or acid medium is particularly 
problematic since it often results in toxicity and reduced bioac-
tivity, thwarting any pharmacological use.4 The substitution of 
the O-glycosidic linkage in 2-deoxyglycosides by a thioether 
bond has been proposed, but the reported methodologies like-
wise suffer from stereoselectivity issues.5 A converse approach 
consisting in the replacement of the endocyclic oxygen atom in 
the 2-deoxysugar glycone unit by nitrogen, to afford a member 
of the archetypic iminosugar glycomimetic family, is conceptu-
ally more appealing.6 In principle, the anticipated lability of 
amino(thio)acetal functional groups can be alleviated by the in-
stallation of N-alkoxycarbonyl substituents, which further al-
lows nucleophilic additions to the α-carbon via acyliminium ion 
intermediates.7 Notwithstanding, attempts to access 2-deoxy-
iminosugar glycosides from the corresponding iminoglycal do-
nors obstinately proceeded with concomitant double bond mi-
gration (Ferrier rearrangement)8 to afford 2,3-unsaturated com-
pounds (Scheme 1, left panel).9  
Scheme 1. Glycosidation Reactions of Iminoglycals and sp2-





In previous work, we found that installing a five-membered 
carbamate ring in the iminosugars, thereby imparting high sp2-
hybridation character to the endocyclic nitrogen, affords bicy-
clic monosaccharide surrogates (sp2-iminosugars) that emulate 
both the function and chemistry of the parent carbohydrates.10 
The carbamate segment is a key integral part of the sp2-imino-
sugar glycomimetic structure, not a protecting group, that fixes 
the conformation about the exocyclic C-5―C-6 bond in the 
gauche-trans conformation (C-4 and O-6 in anti disposition). 
Notably, this subtle structural difference enables glycosylation 
reactions upon activation of glycosyl acetate or fluoride donors 
with Brønsted or Lewis acid promotors and drastically stabi-
lizes axially-oriented anomeric heteroatom substituents 
(Scheme 1, left panel).11 The stereochemical outcome is then 
strictly governed by stereoelectronic effects, mainly the ano-
meric effect, independently of the presence or lack of a ste-
reodirecting group at the C-2 position. We wondered if such fa-
vorable features could be extended to the more demanding 2-
deoxyiminosugars. This endeavor has been addressed in the 
present study, where we have developed an efficient method to 
access the first representatives of this hitherto elusive type of 
glycomimetics. Specifically, we show that gluco-configured bi-
cyclic iminoglycal carbamates (sp2-iminoglycals) can be effi-
ciently transformed into 2-deoxynojirimycin S- and O-glyco-
sides with absolute α-stereoselectivity (Scheme 1, right panel). 
RESULTS AND DISCUSSION 
We initiate our study on the reaction of the diacetylated 
iminoglycal carbamate 112 with octanethiol in the presence of 
BF3·Et2O. This promotor has been found previously to effi-
ciently activate peracetylated sp2-iminosugar donors to give 
iminosugar octyl α-thiogycosides with remarkable antiprolifer-
ative activity.11 Indeed, exclusively α-S-glycosides were de-
tected in the reaction mixture. However, after screening a series 
of reaction conditions we ultimately determined that the target 
2-deoxyiminosugar thioglycoside 2 was always accompanied 
by major proportions of compounds 3 and 4, bearing a second 
octylthio substituent at position C-3 (Scheme 2). It became ap-
parent that formation of a Ferrier-type allylic carbocation fol-
lowed by nucleophilic attack of the thiol at C-3, to give a tran-
sient 2,3-addition product, is favored over the 1,2-addition path-
way. We reasoned that the π-symmetry of the p orbital hosting 
the lone electron pair in the sp2-hybridized carbamate nitrogen 
in 1 enhances the vinylogous anomeric effect, as compared with 
classical glycals, by efficiently overlapping with the π-system 
of the double bond and the σ* antibonding orbital of the axially-
oriented C-3—O-3 bond in a conformation close to an envelope 
E4.
8 Departure of the allylic acetate group upon coordination to 
the Lewis acid is then likely favored by the anchimeric assis-
tance of the vicinal O-4 acetyl (I). The electron withdrawing 
effect of the N-alkoxycarbonyl segment zipping the five-mem-
bered ring disfavors the acyliminium resonant form (IIa) in the 
resulting cationic intermediate, driving thiol attack at position 
C-3. The liberated proton can then activate the 1,2-double bond 
to give a transient acyliminium cation. Addition of a second 
thiol molecule through the α-face is then strongly favored, given 
the enhanced negative hyperconjugation contribution to the 
anomeric effect in sp2-iminosugars (III),11.12 affording the α-thi-
oglycoside as a mixture of the corresponding C-3 epimers 3 and 
4 (Scheme 3). This result is in agreement with the longtime 
known principles of stereoelectronic control governing the con-
densation reactions of iminium ions.13   
Scheme 2. Reaction of Iminoglycal Carbamate 1 with Oc-
tanethiol using BF3·Et2O as promotor. 
 
Scheme 3. Reaction Pathway Leading to 3 and 4. 
 
The fact that no iminoglycal products resulting from the ad-
dition of a single octylthio substituent at C-3 could be isolated 
from the above reaction mixtures indicates that thiol addition to 
the acyliminium cation is kinetically favored. In the glycal se-
ries, It has been reported that CAN in the presence of alcohols 
preferentially supplies 2-deoxyglycosides over 2,3-unsaturated 
derivatives, which is notably different from that observed with 
most Lewis or protic acids.14 The proposed mechanism implies 
the in situ generation of HNO3, which efficiently promotes the 
formation of an oxacarbenium cation and the subsequent trans-
fer of the alkoxide moiety from cerium to the anomeric car-
bon.14,15 We conceived that the higher acidity of thiols as com-
pared to alcohols will facilitate HNO3 development and imino-
glycal activation to the corresponding acyliminium species 
(IV), whereas the lower stability of the Ce(IV)―SR bond (hard 
acid―soft base) will speed thioglycoside formation. The exac-
erbated anomeric effect in sp2-iminosugars was then expected 
to drive thiol addition through the α-face (V).11.12 To our delight, 
the reaction of 1 with octanethiol, dodecanethiol and methyl 
2,3,4-tri-O-acetyl-6-thio-α-D-glucopyranoside16 (6) in the pres-
ence of CAN (0.5 eq) proceeded smoothly in MeCN at room 
temperature to afford the target 2-deoxynojirimycin -thiogly-
coside derivatives 2, 7 and 8 in 68-82% isolated yield after 24-
48 h. The benzylated iminoglycal 5 likewise provided the do-
decyl 2-deoxy-α-thioglycoside 9 using this protocol (see the SI, 
Table S1). Oxidation of the thiol to the corresponding disulfide 
by CAN was an anticipated potential side reaction that would 
also lead to the liberation of HNO3. Although in some of the 
crude reaction mixtures using the octyl and dodecyl thiols the 
corresponding disulfide was detected by MS, it was always in a 
very low proportion, discarding that this is a preferred reaction 
pathway. Neither Ferrier products nor the respective β-anomer 
were detected in the crude reaction mixtures by MS or NMR 
(Scheme 4). 





We next attempted translation of the CAN methodology for 
the purpose of accessing 2-deoxynojirimycin O-glycosides. 
TLC and MS monitoring of the reaction of iminoglycal 1 with 
octanol evidenced that the rate of formation of the correspond-
ing octyl 2-deoxyglycoside was significantly slower when com-
pared with octanethiol. An equimolecular proportion of CAN 
and a five-fold excess of the alcohol were required to achieve 
total consumption of 1 in 48 h at room temperature. Moreover, 
the presence of products incorporating a nitrate group was de-
tected in the crude material. Column chromatography afforded 
an inseparable mixture of the 3,4-di-O-acetyl-2-deoxyimino-
sugar octyl α-glycoside derivative 10 and the nojirimycin 2-ni-
trate ester 11, together with the pure mannojirimycin 2-nitrate 
epimer 12 (8%). The mixture of 10 and 11 was subjected to cat-
alytic (NaOMe/MeOH) deacetylation to afford diols 13 and 14, 
which could then be separated (33% and 6%, respectively) and 
fully characterized, confirming the structural assignment. The 
results can be rationalized assuming that sequential proton ad-
dition (→I)/alkoxyde anion addition to the iminoglycal (→10) 
competes with oxidation of nitrate anion to nitrate radical by 
Ce(IV). Anti-Markovnikov nitrate radical addition to the double 
bond can then occur either through the α or β face, a mechanism 
that is reminiscent of the classical azidonitration reaction of 
glycals.17 The resulting transient imine radical VI can be oxi-
dized by Ce(IV) to the corresponding highly reactive acylimin-
ium cation VII, which finally undergoes glycosidation (→11 
and 12; Scheme 5). 
Scheme 5. CAN-Mediated Reaction of the sp2-Iminoglycal 1 
with Octanol. 
 
A range of different promotors for glycal activation were 
screened aiming to improve the yield of the 2-deoxyiminosugar 





bis(p-nitrophenyl) hydrogen phosphate 
((O2NC6H4O)2P(O)OH),
2i (R)-3,3′-bis[3,5-bis(trifluorome-
thyl)phenyl]-1,1′-binaphthyl-2,2′-diyl hydrogen phosphate 
(15), N,N'-bis[3,5-bis(trifluoromethyl)phenyl]thiourea 
(Schreiner's thiourea; 16),  and the combination of 
(O2NC6H4O)2P(O)OH or 15 and 16 (see the SI, Table S2).
2i  
None of them were effective at mediating the reaction of 1 with 
octanol. The TFA, copper(II) and borane promoters were in-
stead active on the benzylated iminoglycal carbamate 5, afford-
ing 23 as the only reaction product (Scheme 6). Regrettably, in 
all three cases the conversion did not progress beyond 40% even 
using high promotor loadings and prolonged reaction times. 
The gold catalyst as well as the thiourea 16 remained inefficient. 
In sharp contrast, the phosphoric acid derivatives 
(O2NC6H4O)2P(O)OH and 16 in DCM under reflux allowed 
glycosidation of 5 with octanol to go to completion (TLC) in 24 
h. The combined use of the achiral (O2NC6H4O)2P(O)OH pro-
motor and thiourea 16, previously found advantageous for the 
activation of trichloroacetimidate glycosyl donnors,19 did not 
afford any further improvement in our case. However, the com-
bination of 15 and 16 in 1:4 relative proportion led to a signifi-
cant increase in the reaction rate, highlighting the benefit of thi-
ourea-induced acid amplification to favor the formation of the 
acyliminium intermediate and assisting the subsequent attack of 
the glycosyl acceptor. Following previous observations in the 
use of this system for glycosylation reactions,2i, 19 the mecha-
nism depicted in Scheme 7 is proposed. Using the optimized 
conditions, yields over 80% on the alkyl 2-deoxy-α-glycoside 
mimics 23-25 were achieved with octanol, 3-bromopropan-1-ol 
and cyclohexanol, respectively. The potential of the methodol-
ogy to access 2-deoxyiminosugar conjugates and oligosaccha-
rides was further confirmed by using the selectively protected 
serine and monosaccharide derivatives 17, 18 and 19,20 20,21 re-
spectively, as acceptors: the corresponding glycopeptide and di-
saccharide adducts 26, 27 and 28, 29 were thus obtained in 
about 50% yield. The choice of protecting groups is important. 
Thus, 1,2:5,6-diisopropylidene-α-D-glucofuranose (21) under-
went concomitant rearrangement to the 1,2:3,5-diisopropy-
lidene isomer under the reaction conditions, affording an insep-
arable mixture of the α(1→3) and α(1→6) disaccharide mimet-
ics 30 and 31. The 2,3,6-tri-O-benzoyl-α-D-galactopyranoside 
derivative 2222 provided the corresponding α(1→4)-linked 
pseudodisaccharide 32, which could be separated from the ex-
cess of 22 after catalytic (NaOMe/MeOH) debenzoylation 
(→33). Finally, the suitability of 15/16 cooperative catalysis to 
access 2-deoxythioglycosides was investigated. No reaction 
was observed in the case of the acetylated iminoglycal 1 and 
octanethiol. However, the benzylated precursor 5 afforded the 
expected octyl 2-deoxy-α-thioglycoside 34 in 85% yield 
(Scheme 6). 
Scheme 6. Synthesis of 2-Deoxynojirimycin O- and S-Glyco-




Scheme 7. Proposed Acid Amplification Mechanism in Co-
operative Organocatalysis. 
 
It is worth highlighting that no β-liked derivatives were de-
tected in the reactions depicted in Schemes 2, 4, 5 and 6 (see 
also the SI, Tables S1 ans S2), even after short reaction times. 
In previous work regarding the synthesis of thioglycosides from 
sp2-iminosugar (not 2-deoxy) donors, only in a single case the 
β-anomer could be isolated, though in a very minor proportion 
(α:β 20:1).11a In such case, the NMR data supported that the pi-
peridine ring adopted a boat conformation with the β-anomeric 
group in pseudoaxial disposition to fit the anomeric effect. Fur-
ther on, computational calculations supported that formation of 
sp2-iminosugar α-O-glycosides, which can fulfil the anomeric 
effect in the more stable chair conformation, through acylimin-
ium intermediates is both kinetically and thermodynamically 
favored over the corresponding β-O-glycosides.12 We can thus 
reasonably assume that in the 2-deoxy series here reported the 
situation is similar and that once generated the acyliminium cat-
ion from the glycal precursor, the extremely strong anomeric 
effect stabilizes both the transition state leading to the α-anomer 
and the final 2-deoxy α-glycoside. 
CONCLUSIONS 
In summary, we have achieved the synthesis of a series of 2-
deoxynojirimycin (thio)glycosides, the first representatives of 
the iminosugar-type 2-deoxyglycoside mimetics. Unlike previ-
ous attempts using monocyclic iminoglycal precursors, which 
led to 2,3-unsaturated products, the reaction of bicyclic imino-
glycal carbamates (sp2-iminoglycals) with thiols or alcohols en-
ables efficient access to the target N,S- or N,O-acetals, upon 
activation with CAN or by cooperative catalysis between the 
chiral  (R)-BINOL phosphoric acid derivative 15 and Schrein-
er's thiourea 16, under conditions that prevent intramolecular 
rearrangements. The two methods are complementary: CAN ac-
tivation tolerates acetate or benzyl protecting groups in the sp2-
iminoglycal, but is restricted to thiol partners, whereas cooper-
ative organocatalysis is equally efficient for thiols or alcohols, 
but is incompatible with ester protecting groups in the imino-
glycal substrate. In all cases, we believe that the reaction pro-
ceeds via the corresponding short-lived N-acyliminium ion in-
termediate that is rapidly trapped by the SH or OH nucleophile 
under strict control of the anomeric effect, affording exclusively 
the α-S- or O-glycosidic linkage. Altogether, our results open 
new avenues for the synthesis of 2-deoxyglycoside mimics re-
sistant to acid-mediated or enzymatic hydrolysis. 
EXPERIMENTAL SECTION  
Materials and General Methods. Reagents and solvents 
were purchased from commercial sources and used without fur-
ther purification. Optical rotations were measured with a 
JASCO P-2000 Polarimeter, using a sodium lamp ( = 589 nm) 
at 22 ̊ C in 1 cm or 1 dm tubes. 1 H (13C) NMR experiments were 
performed at 300 (75.5), 400 (100.1) and 500 (125.7) MHz. 2-
D COSY, HSQC and 1D-TOCSY experiments were carried out 
to assist on signal assignment. For ESI mass spectra, 0.1 pm 
sample concentrations were used, the mobile phase consisting 
of 50% aq MeCN at 0.1 mL/min. Thin-layer chromatography 
was performed on precoated TLC plates, silica gel 30F-245, 
with visualization by UV light and by carring with 10% H2SO4 
or 0.2% w/v cerium (IV) sulphate-5% ammonium molybdate in 
2 M H2SO4 or 0.1% ninhydrin in EtOH. Column chromatog-
raphy was performed on Silica Gel 60 AC.C (63-200 mm) 
Sigma Aldrich and Geduran Si 60 Merck (40-63 mm). All com-
 
 
pounds were purified to ≥95% purity as determined by ele-
mental microanalysis results obtained on a CHNS-TruSpect® 
Micro elemental analyzer (Instituto de Investigaciones 
Químicas de Sevilla, Spain) from vacuum-dried samples. The 
analytical results for C, H, N and S were within ±0.4 of the the-
oretical values. Conventional deacetylation was conducted by 
addition of NaOMe (0.1 eq/Ac mol) in MeOH at room temper-
ature, followed by neutralization with solid CO2, evaporation of 
the solvent and purification by column chromatography. The 
starting derivatives 3,4-di-O-acetyl-5N,6O-(oxomethyli-
dene)nojirimycin iminoglycal (1),12  methyl 2,3,4-tri-O-acetyl-
6-thio-α-D-glucopyranoside (6),23 Fmoc-Ser-OtBu (18),24 me-
thyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (19),21 1,2-O-iso-
propylidene-5,6-O-(o-xylylene)-α-D-glucofuranose (20),18 and 
methyl 2,3,6-tri-O-benzoyl-α-D-galactopyranoside (22)22 were 
prepared according to previously reported protocols. 
3,4-Di-O-benzyl-5N,6O-oxomethylidenenojirimycin 
Iminoglycal (5). To a solution of iminoglycal 1 (193 mg, 0.76 
mmol) in MeOH (4 mL), NaOMe (1 M) (152 L, 0.152 mmol) 
was added and the reaction mixture was stirred for 20 min, neu-
tralized with solid CO2 and concentrated under reduced pres-
sure. The resulting residue was purified by column chromatog-
raphy (EtOAc) to yield the fully unprotected iminoglycal, 
namely 5N,6O-oxomethylidenenojirimycin iminoglycal. Yield: 
125 mg (96%). Rf 0.23 (9:1 EtOAc-cyclohexane). [α]D +73.7 (c 
1.0 in MeOH). 1H NMR (300 MHz, CD3OD) δ 6.50 (dd, 1 H, 
J1,2 = 7.8 Hz, J1,3 = 2.1 Hz, H-1), 4.99 (dd, 1 H, J2,3 = 2.1 Hz, H-
2), 4.64 (t, 1 H, J6a,6b = J5,6a = 9.0 Hz, H-6a), 4.28-4.19 (m, 2 H, 
H-3, H-6b), 4.00 (bq, 1 H, J4,5 = J5,6b = 9.0 Hz, H-5), 3.55 (dd, 1 
H, J3,4 = 7.8 Hz, H-4). 
13C NMR (75.5 MHz, CD3OD) δ 155.9 
(CO), 122.0 (C-1), 112.8 (C-2), 74.4 (C-4), 72.0 (C-3), 69.1 (C-
6), 56.8 (C-5). ESIMS: m/z 194.0 [M + Na]+. Anal. Calcd for 
C7H9NO4: C, 49.12; H, 5.30; N, 8.18. Found: C, 49.19; H, 5.54; 
N, 7.90. 
To a solution of the above 5N,6O-
oxomethylidenenojirimycin iminoglycal (130 mg, 0.76 mmol) 
in dry DMF (4 mL) under Ar atmosphere, NaH (95%, 91 mg, 
3.80 mmol) was added at 0 ºC and the mixture was stirred for 
10 min. Benzyl bromide (362 L, 3.04 mmol) was then added 
dropwise and the reaction mixture was stirred for 17 h. Water 
(20 mL) was then added and the aqueous phase was extracted 
with Et2O (5 x 30 mL), dried (MgSO4) and concentrated under 
reduced pressure. The resulting residue was purified by column 
chromatography (1:3 EtOAc-cyclohexane). Yield: 200 mg 
(75%). Rf 0.76 (1:1 EtOAc-cyclohexane). [α]D +45.2 (c 1.0 in 
DCM). 1H NMR (300 MHz, CDCl3) δ 7.50-7.20 (m, 10 H, Ph), 
6.60 (dd, 1 H, J1,2 = 7.8 Hz, J1,3 = 1.5 Hz, H-1), 5.13 (dd, 1 H, 
J2,3 = 2.1 Hz, H-2), 4.94 (d, 1 H, 
2JH,H = 11.7 Hz, OCHPh), 4.76 
(d, 1 H, 2JH,H = 11.7 Hz, OCHPh), 4.71 (d, 1 H, OCHPh), 4.66 
(d, 1 H, OCHPh), 4.48 (dd, 1 H, J6a,6b = 8.7 Hz, J5,6a = 7.8 Hz, 
H-6a), 4.42 (dt, 1 H, J3,4 = 7.5 Hz, H-3), 4.03-3.91 (m, 1 H, H-
5), 3.80 (t, 1 H, J5,6b = 8.7 Hz, H-6b), 3.68 (dd, 1 H, J4,5 = 10.0 
Hz, H-4). 13C NMR (75.5 MHz, CDCl3) δ 153.4 (CO), 137.8-
127.9 (OCH2Ph), 122.2 (C-1), 107.3 (C-2), 79.0 (C-3), 77.6 (C-
4), 74.0, 71.4 (CH2Ph), 67.6 (C-6), 54.4 (C-5). ESIMS: m/z 
374.2 [M + Na]+. Anal. Calcd for C21H21NO4: C, 71.78; H, 6.02; 
N, 3.99. Found: C, 71.90; H, 6.19; N, 3.81. 
Thioglycosylation Procedure Using BF3·Et2O. To a solution 
of 3,4-di-O-acetyl-5N,6O-(oxomethylidene)nojirimycin glucal (1; 
54 mg, 0.21 mmol) in dry DCM (5 mL) under Ar atmosphere, 1-
octanethiol (42 L, 0.24 mmol, 1.15 eq) and BF3.Et2O (95 L, 0.76 
mmol, 3.6 eq) were added at 0 °C and the reaction was stirred for 
60 min at RT, diluted with DCM, washed with aqueous NaHCO3 
(2 x 10 mL), brine (10 mL), dried (MgSO4), filtered and concen-
trated under reduced pressure. The resulting mixture was purified 
by column chromatography (1:5 EtOAc-cyclohexane) to afford 
compounds 2-4 as amorphous solids. 
(1R)-3,4-Di-O-acetyl-1-octylthio-5N,6O-oxomethylidene-2-
deoxynojirimycin (2). Yield: 11 mg (13%). Rf 0.53 (1:1 EtOAc-cy-
clohexane). [α]D +71.3 (c 1.1 in DCM). 1H NMR (300 MHz, 
CDCl3) δ 5.28 (dd, 1 H, J1,2a = 5.7 Hz, J1,2b = 1.2 Hz, H-1), 5.22 
(ddd, 1 H, J2a,3 = 11.7 Hz, J3,4 = 9.3 Hz, J2b,3 = 4.8 Hz, H-3), 4.80 
(t, 1 H, J4,5 = 9.3 Hz, H-4),  4.37 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-
6a), 4.20 (dd, 1 H, J5,6b = 6.0 Hz, H-6b), 4.09 (ddd, 1 H, H-5), 2.57 
(ddd, 1 H, 2JH,H = 12.9 Hz, 3JH,H = 8.1 Hz, 3JH,H = 6.3 Hz, SCH2), 
2.43 (ddd, 1 H, SCH2), 2.20 (ddd, 1 H, J2a,2b = 13.2 Hz, H-2b), 2.00-
1.96 (2 s, 6 H, MeCO), 2.05-1.93 (m, 1 H, H-2a), 1.66-1.10 (m, 12 
H, CH2), 0.81 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR (75.5 MHz, 
CDCl3) δ 170.2-169.7 (CO ester), 155.7 (CO carbamate), 73.5 (C-
4), 68.9 (C-3), 66.2 (C-6), 54.4 (C-1), 51.9 (C-5), 34.6 (C-2), 31.7-
22.6 (CH2), 20.8-20.6 (MeCO), 14.1 (CH3). ESIMS: m/z 424.2 [M 
+ Na]+. Anal. Calcd for C19H31NO6S: C, 56.84; H, 7.78; N, 3.49; S, 
7.98. Found: C, 56.98; H, 7.85; N, 3.57; S, 7.72. 
(1R)-4-O-Acetyl-1,3-di-octylthio-5N,6O-oxomethylidene-2-
deoxynojirimycin (3). Yield: 35 mg (34%). Rf 0.61 (1:4 EtOAc-
cyclohexane). [α]D +36.3 (c 1.0 in DCM). 1H NMR (500 MHz, 
CDCl3) δ 5.28 (d, 1 H, J1,2a = 5.0 Hz, H-1), 4.70 (t, 1 H, J4,5 = J3,4 
= 9.6 Hz, H-4), 4.40 (t, 1 H, J6a,6b = J5,6a = 8.7 Hz, H-6a), 4.19 (dd, 
1 H, J5,6b = 6.6 Hz, H-6b), 4.06 (td, 1 H, H-5), 3.01 (ddd, 1 H, J2a,3 
= 13.0 Hz, J2b,3 = 3.9 Hz, H-3), 2.64 (ddd, 1 H, 2JH,H = 12.9 Hz, 
3JH,H = 8.1 Hz, 3JH,H = 6.1 Hz, SCH2), 2.56-2.45 (m, 3 H, SCH2), 
2.27 (dd, 1 H, J2a,2b = 14.0 Hz, H-2b), 2.12 (s, 3 H, MeCO), 2.16-
2.07 (m, 1 H, H-2a), 1.74-1.19 (m, 24 H, CH2), 0.87 (t, 6 H, 3JH,H 
= 6.5 Hz, CH3). 13C NMR (125.7 MHz, CDCl3) δ 170.2 (CO ester), 
155.8 (CO carbamate), 74.2 (C-4), 66.6 (C-6), 55.5 (C-1), 53.0 (C-
5), 42.5 (C-3), 37.3 (C-2), 31.8 (SCH2), 31.1-22.6 (CH2), 20.8 
(MeCO), 14.1 (CH3). ESIMS: m/z 510.1 [M + Na]+. Anal. Calcd 
for C25H45NO4S2: C, 61.56; H, 9.30; N, 2.87; S, 13.15. Found: C, 
61.39; H, 8.99; N, 2.84; S, 12.82 
(1R)-4-O-Acetyl-1,3-di-octylthio-5N,6O-oxomethylidene-2-
deoxyallonojirimycin (4). Yield: 6 mg (6%). Rf 0.53 (1:2 EtOAc-
cyclohexane). [α]D +65.5 (c 1.0 in DCM). 1H NMR (500 MHz, 
CDCl3) δ 5.22 (dd, 1 H, J1,2a = 7.0 Hz, J1,2b = 2.5 Hz, H-1), 4.75 
(dd, 1 H, J4,5 = 9.0 Hz, J3,4 = 4.0 Hz, H-4), 4.46 (t, 1 H, J6a,6b = J5,6a 
= 9.0 Hz, H-6a), 4.32 (td, 1 H, J5,6b = 5.5 Hz, H-5), 4.15 (dd, 1 H, 
H-6b), 3.38 (q, 1 H, J2a,3 = J2b,3 = 4.0 Hz, H-3), 2.68 (ddd, 1 H, 2JH,H 
= 12.8 Hz, 3JH,H = 8.3 Hz, 3JH,H = 6.1 Hz, SCH), 2.59-2.46 (m, 4 H, 
SCH2, SCH, H-2a), 2.22 (ddd, 1 H, J2a,2b = 15.0 Hz, H-2b), 2.11 (s, 
3 H, MeCO), 1.70-1.20 (m, 24 H, CH2), 0.88 (t, 3 H, 3JH,H = 6.7 Hz, 
CH3), 0.87 (t, 3 H, 3JH,H = 6.7 Hz, CH3). 13C NMR (125.7 MHz, 
CDCl3) δ 170.3 (CO ester), 156.1 (CO carbamate), 74.5 (C-4), 66.1 
(C-6), 55.0 (C-1), 49.6 (C-5), 42.8 (C-3), 35.2 (C-2), 34.2-22.6 
(CH2), 20.8 (MeCO), 14.1 (CH3). ESIMS: m/z 510.5 [M + Na]+. 
HRFABMS Calcd for C25H45NO4S2Na [M + Na]+ 510.2688, found 
510.2689. 
General Thioglycosylation Procedure Using CAN. To a 
stirred solution of the di-O-acetyl- or di-O-benzyl glucal (1 or 5; 
0.20 mmol) and CAN (0.5 eq) in dry MeCN (2 mL) under Ar at-
mosphere, the corresponding thiol derivative (0.40 mmol, 2.0 eq) 
was added and the reaction mixture was stirred for 24-48 h at RT 
(see the SI Table S1, entries 1-7, for a full account of the assayed 
reaction conditions). Et2O (20 mL) and H2O (20 mL) were then 
added and the aqueous phase was extracted with Et2O (2 x 10 mL) 
and the organic layer was dried (MgSO4), filtered and concentrated 
under reduced pressure. The resulting residue was purified by col-




deoxynojirimycin (2). Column chromatography (1:4 → 1:2 EtOAc-
cyclohexane). Yield: 152 mg (68%).  
(1R)-3,4-Di-O-acetyl-1-dodecylthio-5N,6O-oxomethylidene-2-
deoxynojirimycin (7). Column chromatography (1:3 → 1:2 EtOAc-
cyclohexane). Yield: 59 mg (74%). Rf 0.62 (1:1 EtOAc-
cyclohexane). [α]D +65.3 (c 1.0 in DCM). 1H NMR (300 MHz, 
CDCl3) δ 5.30 (dd, 1 H, J1,2a = 5.6 Hz, J1,2b = 1.5 Hz, H-1), 5.25 
(ddd, 1 H, J2a,3 = 11.7 Hz, J3,4 = 9.5 Hz, J2b,3 = 4.8 Hz, H-3), 4.83 
(t, 1 H, J4,5 = 9.5 Hz, H-4),  4.40 (dd, 1 H, J6a,6b = 9.0 Hz, J5,6a = 8.4 
Hz, H-6a), 4.23 (dd, 1 H, J5,6b = 6.0 Hz, H-6b), 4.11 (ddd, 1 H, H-
5), 2.70-2.40 (m, 2 H, SCH2), 2.23 (ddd, 1 H, J2a,2b = 13.2 Hz, H-
2b), 2.04-1.99 (2 s, 6 H, MeCO), 2.10-1.95 (m, 1 H, H-2a), 1.70-
1.10 (m, 20 H, CH2), 0.84 (t, 3 H, 3JH,H = 6.7 Hz, CH3). 13C NMR 
(75.5 MHz, CDCl3) δ 170.2-169.7 (CO ester), 155.6 (CO 
carbamate), 73.5 (C-4), 68.9 (C-3), 66.1 (C-6), 54.4 (C-1), 51.9 (C-
5), 34.6 (C-2), 31.9-22.6 (CH2), 20.8-20.6 (MeCO), 14.1 (CH3). 
ESIMS: m/z 480.2 [M + Na]+. Anal. Calcd for C23H39NO6S: C, 




(8). Column chromatography (1:4 → 1:2 EtOAc-cyclohexane). 
Yield: 111 mg (82%). Rf 0.18 (1:1 EtOAc-cyclohexane). [α]D 
+110.3 (c 1.5 in DCM). 1H NMR (300 MHz, CDCl3) δ 5.44 (t, 1 H, 
J2,3 = J3,4 = 9.6 Hz, H-3), 5.37 (bd, 1 H, J1’,2a’ = 4.8 Hz, H-1’), 5.22 
(ddd, 1 H, J2a’,3’ = 11.7 Hz, J3’,4’ = 9.6 Hz, J2b’,3’ = 4.8 Hz, H-3’), 
5.04 (t, 1 H, J4,5 = 9.6 Hz, H-4), 4.92-4.78 (m, 3 H, H-1, H-2, H-
4’), 4.50-4.40 (m, 1 H, H-6a’), 4.25-4.11 (m, 2 H, H-5’, H-6b’), 
3.99 (ddd, 1 H, J5,6b = 6.0 Hz, J5,6a = 3.3 Hz, H-5), 3.41 (s, 3 H, 
OMe), 3.03 (dd, 1 H, J6a,6b = 14.0 Hz, H-6a), 2.63 (dd, 1 H, H-6b), 
2.28 (ddd, 1 H, J2a’,2b’ = 13.5 Hz, J1,2b = 1.5 Hz, H-2b’), 2.06-1.98 
(5 s, 15 H, MeCO), 2.11-2.04 (m, 1 H, H-2a'). 13C NMR (75.5 MHz, 
CDCl3) δ 170.3-169.7 (CO ester), 156.0 (CO carbamate), 96.6 (C-
1), 73.6 (C-4’), 70.8 (C-2), 70.6 (C-4), 70.0 (C-3), 68.7 (C-3’), 68.3 
(C-5), 66.5 (C-6’), 55.5 (OMe), 55.0 (C-1’), 51.9 (C-5’), 34.6 (C-
2’), 32.0 (C-6), 20.8-20.6 (MeCO). ESIMS: m/z 614.2 [M + Na]+. 
Anal. Calcd for C24H33NO14S: C, 48.73; H, 5.62; N, 2.37; S, 5.42. 
Found: C, 48.87; H, 5.73; N, 2.12; S, 5.19. 
(1R)-3,4-Di-O-benzyl-1-dodecylthio-5N,6O-oxomethylidene-
2-deoxynojirimycin (9). Column chromatography (1:4 EtOAc-
cyclohexane). Yield: 18 mg (68%). Rf 0.50 (1:3 EtOAc-
cyclohexane). [α]D +93.6 (c 1.0 in DCM). 1H NMR (300 MHz, 
CDCl3) δ 7.29-7.19 (m, 10 H, Ph), 5.21 (d, 1 H, J1,2a = 6.0 Hz, H-
1), 4.89 (d, 1 H, 2JH,H = 11.4 Hz, OCH2Ph), 4.61 (d, 1 H, 2JH,H = 
11.4 Hz, OCH2Ph), 4.58 (d, 1 H, OCH2Ph), 4.55 (d, 1 H, OCH2Ph), 
4.29 (t, 1 H, J6a,6b = J5,6a = 8.5 Hz, H-6a), 3.94-3.80 (m, 2 H, H-3, 
H-5), 3.75 (dd, 1 H, J5,6b = 6.0 Hz, H-6b), 3.21 (t, 1 H, J3,4 = J4,5 = 
9.0 Hz, H-4), 2.54 (ddd, 1 H, 2JH,H = 12.9 Hz, 3JH,H = 8.1 Hz, 3JH,H 
= 6.0 Hz, SCH2), 2.38 (ddd, 1 H, SCH2), 2.21 (ddd, 1 H, J2a,2b = 
13.5 Hz, J2b,3 = 4.5 Hz, J1,2b = 1.5 Hz, H-2b), 1.81 (ddd, 1 H, J2a,3 
= 11.7 Hz, H-2a), 1.60-1.10 (m, 20 H, CH2), 0.81 (t, 3 H, 3JH,H = 
7.0 Hz, CH3). 13C NMR (75.5 MHz, CDCl3) δ 156.0 (CO), 137.9-
127.8 (Ph), 81.6 (C-4), 78.2 (C-3), 74.8, 72.2 (CH2Ph), 66.6 (C-6), 
54.9 (C-1), 52.5 (C-5), 35.0 (C-2), 31.9-22.7 (CH2), 14.1 (CH3). 
ESIMS: m/z 576.4 [M + Na]+. Anal. Calcd for C33H47NO4S: C, 
71.57; H, 8.55; N, 2.53; S, 5.79. Found: C, 71.38; H, 8.30; N, 2.22; 
S, 5.57. 
Glycosylation Procedure Using CAN. To a stirred solution of 
the sp2-iminoglycal derivative 1 (111 mg, 0.43 mmol) and CAN 
(236 mg, 0.43 mmol, 1.0 eq) in dry MeCN (3 mL) under Ar atmos-
phere, 1-octanol (0.34 mL, 2.15 mmol, 5.0 eq) was added and the 
reaction mixture was stirred for 48 h at RT (see the SI Table S2, 
entry 10). Et2O (20 mL) and H2O (20 mL) were next added, the 
aqueous phase was extracted with Et2O (2 x 10 mL) and the organic 
layer was dried (MgSO4), filtered and concentrated under reduced 
pressure. The resulting residue was purified by column chromatog-
raphy (1:3 EtOAc-cyclohexane) to afford the 1-O-octyl-2-nitrate 
ester 12 (15 mg; 8%) together with a mixture of 10 and 11 in a 3:1 
ratio. Conventional O-deacetylation reaction of the later fraction as 
described in General Methods and column chromatography (1:2 
EtOAc-cyclohexane) of the resulting fully unprotected product af-
forded the pure diols 13 (33%) and 14 (6%). 
(1R)-3,4-Di-O-acetyl-2-nitrate-1-O-octyl-5N,6O-
oxomethylidenemannojirimycin (12). Yield: 15 mg (8%). Rf 0.35 
(1:2 EtOAc-cyclohexane). [α]D -5.2 (c 1.3 in DCM). 1H NMR (300 
MHz, CDCl3) δ 5.51-5.43 (m, 2H, H-2, H-3), 5.23 (d, 1H, J1,2 = 2.1 
Hz, H-1), 5.12 (t, 1H, J3,4 = J4,5 = 9.5 Hz, H-4),  4.46 (dd, 1H, J6a,6b 
= 9.0 Hz, J5,6a = 8.0 Hz, H-6a), 4.34 (dd, 1H, J5,6b = 6.6 Hz, H-6b), 
3.90 (ddd, 1 H, H-5), 3.64-3.50 (m, 2H, OCH2), 2.07-2.06 (2 s, 6H, 
MeCO), 1.70-1.20 (m, 12 H, CH2), 0.88 (t, 3 H, 3JH,H = 7.0 Hz, 
CH3). 13C-NMR (75.5 MHz, CDCl3) δ 169.9-169.6 (CO ester), 
156.1 (CO carbamate), 79.6 (C-1), 77.2 (C-2), 69.7 (C-4), 69.3 
(OCH2), 68.0 (C-3), 66.8 (C-6), 52.5 (C-5), 31.8-22.6 (CH2), 20.5 
(MeCO), 14.1 (CH3). ESIMS: m/z 469.2 [M + Na]+. ESI-HRMS 
Calcd for C19H30N2O10Na [M + Na]+ 469.1793, found 469.1794. 
(1R)-1-O-Octyl-5N,6O-oxomethylidene-2-deoxynojirimycin 
(13). Yield: 43 mg (33%, two steps). Rf 0.30 (2:1 EtOAc-cyclohex-
ane). [α]D +36.3 (c 1.4 in MeOH). 1H NMR (300 MHz, CD3OD) δ 
5.09 (d, 1 H, J1,2a = 3.6 Hz, J1,2b = 1.5 Hz, H-1), 4.54 (t, 1 H, J6a,6b 
= J5,6a = 9.0 Hz, H-6a), 4.26 (dd, 1 H, J5,6b = 6.0 Hz, H-6b), 3.79 
(ddd, 1 H, J2a,3 = 11.7 Hz, J3,4 = 9.0 Hz, J2b,3 =  4.5 Hz, H-3), 3.69 
(td, 1 H, J4,5 = 9.0 Hz, H-5), 3.55-3.35 (m, 2 H, OCH2), 3.22 (t, 1 
H, H-4),  2.15 (ddd, 1 H, J2a,2b = 13.5 Hz, H-2b), 1.66-1.50 (m, 3 
H, H-2a, CH2), 1.45-1.20 (m, 10 H, CH2), 0.91 (t, 3 H, 3JH,H = 7.0 
Hz, CH3). 13C NMR (75.5 MHz, CD3OD) 158.8 (CO), 81.2 (C-1), 
77.2 (C-4), 69.6 (C-3), 68.9 (OCH2), 68.3 (C-6), 55.5 (C-5), 38.4 
(C-2), 33.1-23.7 (CH2), 14.4 (CH3). ESIMS: m/z 324.1 [M + Na]+. 
Anal. Calcd for C15H27NO5S: C, 59.78; H, 9.03; N, 4.65. Found: C, 
59.54; H, 8.87; N, 4.41. 
(1R)-2-Nitrate-1-O-octyl-5N,6O-oxomethylidenenojirimycin 
(14). Yield: 11 mg (6% in two steps). Rf 0.29 (2:1 EtOAc-cyclo-
hexane). [α]D +58.7 (c 0.9 in MeOH). 1H NMR (300 MHz, CD3OD) 
δ 5.36 (d, 1 H, J1,2 = 4.2 Hz, H-1), 4.92 (dd, 1 H, J2,3 = 10.0 Hz, H-
2), 4.60 (t, 1 H, J6a,6b = J5,6a = 9.0 Hz, H-6a), 4.29 (dd, 1 H, J5,6b = 
6.3 Hz, H-6b), 3.79 (t, 1 H, J3,4 = 10.0 Hz, H-3), 3.78-3.70 (m, 1 H, 
H-5), 3.66-3.39 (m, 3 H, H-4, OCH2), 1.70-1.20 (m, 12 H, CH2), 
0.91 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR (75.5 MHz, CD3OD) 
δ 158.4 (CO), 82.0 (C-2), 79.9 (C-1), 75.8 (C-4), 71.0 (C-3), 69.6 
(OCH2), 68.6 (C-6), 54.3 (C-5), 32.9-23.7 (CH2), 14.0 (CH3). 
ESIMS: m/z 385.1 [M + Na]+. ESI-HRMS Calcd for C15H26N2O8Na 
[M + Na]+ 385.1581, found 385.1577. 
General Glycosylation/Thioglycosylation Procedure by Co-
operative Organocatalysis. The benzylated iminoglycal donor 5 
(20 mg, 57 mol) and the corresponding acceptor (86 mol, 1.5 eq) 
were placed into a microwave vial under vacuum for 1 h under N2 
atmosphere. A mixture of the BINOL-derived phosphoric acid (R)-
15 (6 mol) and Schreiner’s thiourea 16 (23 mol) in anhydrous 
DCM (~1 mL, 0.1 M) were stirred for 30 min and then added to the 
microwave vial containing the donor and acceptor. The reaction 
mixture was refluxed for 3-24 h, concentrated under reduced pres-
sure and purified by column chromatography using the solvent in-
dicated in each case (see the SI Table S1, entries 8 and 9, and Table 
S2 for a full account of the assayed reaction conditions). 
(1R)-3,4-Di-O-benzyl-1-O-octyl-5N,6O-oxomethylidene-2-
deoxynojirimycin (23). Column chromatography (1:6 → 1:4 
EtOAc-cyclohexane). Yield: 22 mg (80%). Rf 0.7 (1:2 EtOAc-
cyclohexane). [α]D +44.7 (c 1.0 in DCM). 1H NMR (500 MHz, 
CDCl3) δ 7.28-7.18 (m, 10 H, Ph), 5.05 (dd, 1 H, J1,2b = 3.7 Hz, J1,2a 
= 1.8 Hz, H-1), 4.89, 4.58 (2 d, 2 H, 2JH,H = 11.6 Hz, CHPh), 4.63, 
 
 
4.57 (2 d, 1 H, 2JH,H = 11.4 Hz, CHPh), 4.29 (t, 1 H, J6a,6b = J5,6a = 
8.6 Hz, H-6a), 3.90 (m, 1 H, H-3), 3.75 (dd, 1 H, J5,6b = 6.3 Hz, H-
6b), 3.70-3.65 (m, 1 H, H-5), 3.38-3.29 (m, 2 H, OCH2), 3.24 (t, 1 
H, J3,4 = J4,5 = 9.0 Hz, H-4), 2.30 (ddd, 1 H, J2a,2b = 13.2 Hz, J2a,3 = 
4.7 Hz, H-2a), 1.54 (ddd, 1 H, J2b,3 = 11.2 Hz, H-2b), 1.47-1.43 (m, 
1 H, OCH2CH2), 1.20 (m, 10 H, CH2), 0.81 (t, 3 H, JH,H = 7.0 Hz, 
CH3). 13C NMR (125.7 MHz, CDCl3) δ 156.7 (CO), 138.4-138.3 
(Ph), 128.9-128.0 (Ph), 81.7 (C-4), 79.7 (C-1), 77.9 (C-3), 75.0, 
72.4 (CH2Ph), 68.3 (OCH2), 67.2 (C-6), 53.4 (C-5), 35.3 (C-2), 
32.1-23.0 (CH2), 14.3 (CH3). ESIMS: m/z 504.3 [M + Na]+. ESI-
HRMS Calcd for C29H39NO5Na [M + Na]+ 504.2720, found 
504.2716. 
(1R)-3,4-Di-O-benzyl-1-O-(3-bromopropyl)-5N,6O-
oxomethylidene-2-deoxynojirimycin (24). Column chromatography 
(1:4 EtOAc-hexane). Yield: 21 mg (87%). Rf 0.5 (1:2 EtOAc-
cyclohexane). [α]D +54.3 (c 1.0 in DCM). 1H NMR (500 MHz, 
CDCl3) δ 7.30-7.18 (m, 10 H, Ph), 5.07 (dd, 1 H, J1,2b =  4.0 Hz, 
J1,2a = 1.8 Hz, H-1), 4.89, 4.59 (2 d, 2 H, 2JH,H = 11.5 Hz, CHPh), 
4.63, 4.59 (2 d, 1 H, 2JH,H = 11.5 Hz, CHPh), 4.30 (t, 1 H, J6a,6b = 
J5,6a = 8.24 Hz, H-6a), 3.86 (m, 1 H, H-3), 3.76-3.67 (m, 2 H, H-5, 
H-6b), 3.57 (m, 1 H, OCH2), 3.44 (m, 1 H, OCH2), 3.39 (t, 2 H, JH,H 
= JH,H = 6.7 Hz, CH2Br), 3.25 (t, 1 H, J3,4 = J4,5 =  9.2 Hz, H-4), 
2.29 (ddd, 1 H, J2a,2b = 13.2 Hz, J2a,3 = 4.7 Hz, H-2a), 2.08-1.99 (m, 
1 H, CH2), 1.98-1.90 (m, 1 H, CH2), 1.56 (ddd, 1 H, J2b,3 = 11.3 Hz, 
H-2b). 13C NMR (125.7 MHz, CDCl3) δ 156.7 (CO), 138.3-139.1 
(Ph), 128.8-127.9 (Ph), 81.5 (C-4), 79.6 (C-1), 77.6 (C-3), 75.0-
72.3 (CH2Ph), 67.1 (C-6), 65.0 (OCH2), 53.4 (C-5), 35.0 (C-2), 
32.2 (CH2), 30.4 (CH2Br).  ESIMS: m/z 512.1 [M + Na]+. ESI-
HRMS Calcd for C24H28BrN4NaO5 [M + Na]+ 512.1043, found 
512.1036. 
(1R)-3,4-Di-O-benzyl-1-O-(cyclohexyl)-5N,6O-
oxomethylidene-2-deoxynojirimycin (25). Column chromatography 
(1:30 → 1:20 → 1:10 EtOAc-toluene). Yield: 21 mg (80%). Rf 0.7 
(1:2 EtOAc-toluene). [α]D +41.0 (c 1.0 in DCM). 1H NMR (500 
MHz, CDCl3) δ 7.30-7.18 (m, 10 H, Ph), 5.22 (dd, 1 H, J1,2 = 4.1 
Hz, J1,2a = 1.9 Hz, H-1), 4.90, 4.58 (2 d, 2 H, 2JH,H = 11.6 Hz, 
CHPh), 4.63, 4.57 (2 d, 1 H, 2JH,H = 11.2 Hz, CHPh), 4.28 (t, 1 H, 
t, J5,6a = J6a,6b = 8.2 Hz, H-6a), 3.96-3.91 (m, 1 H, H-3), 3.76 (dd, 1 
H, J6a,6b = 8.7 Hz, J5,6b = 5.6 Hz, H-6b), 3.73-3.68 (m, 1 H, H-5), 
3.34-3.30 (m, 1 H, OCH), 3.24 (t, 1 H, J3,4 = J4,5 = 8.9 Hz, H-4), 
2.25 (ddd, 1 H, J2a,2b = 13.2 Hz, J2a,3 = 4.6 Hz, H-2a), 1.86 (m, 1 H, 
CH2), 1.62 (m, 3 H, CH2), 1.54 (ddd, 1 H, H-2b), 1.43 (m, 1 H, 
CH2), 1.18 (m, 4 H, CH2). 13C NMR (125.7 MHz, CDCl3) δ 156.6 
(CO), 138.6-138.4 (Ph), 128.9-128.1 (Ph), 81.9 (C-4), 78.0 (C-3), 
77.3 (C-1), 75.2 (CH2Ph), 74.9 (OCH), 72.4 (CH2Ph), 67.1 (C-6), 
53.5 (C-5), 35.8 (C-2), 33.6, 31.6, 26.0, 24.4, 24.1 (CH2). ESIMS: 
m/z 474.2 [M + Na]+. ESI-HRMS Calcd for C27H33NO5Na [M + 
Na]+ 474.2251, found 474.2244. 
(1R)-3,4-Di-O-benzyl-1-O-(Boc-l-Ser-OMe)-5N,6O-
oxomethylidene-2-deoxynojirimycin (26). Column chromatography 
(1:4 → 1:3 → 1:2 EtOAc-cyclohexane). Yield: 11 mg (67%). Rf 
0.5 (1:2 EtOAc-hexane). [α]D +80.0 (c 1.0 in DCM). 1H NMR (400 
MHz, CDCl3) δ 7.37-7.26 (m, 10 H, Ph), 5.20 (d, 1 H, JNH,CH = 
9.3Hz, NH), 5.11 (dd, 1 H, dd, 1 H, J1,2b = 4.0 Hz, J1,2a = 1.8 Hz, 
H-1), 4.96, 4.64 (2 d, 2 H, 2JH,H = 11.3 Hz, CHPh), 4.68, 4.65 (2 d, 
1 H, 2JH,H = 11.5 Hz, CHPh), 4.45 (d, 1 H, CHNH), 4.36 (t, 1 H, 
J6a,6b = J5,6a = 8.6 Hz, H-6a), 3.88 (m, 1 H, H-3), 3.83-3.78 (m, 2 H, 
OCH2, H-6b), 3.76 (s, 3 H, OCH3), 3.73-3.68 (m, 2 H, H-5, OCH2), 
3.29 (t, 1 H, J3,4 = J4,5 = 9.1 Hz, H-4), 2.30 (ddd, 1 H, J2a,2b = 13.3 
Hz, J2a,3 = 4.7 Hz, H-2a), 1.63-1.59 (ddd, 1 H, H-2b), 1.46 (s, 9 H, 
CH3). 13C NMR (101.1 MHz, CDCl3) δ 171.2 (CO ester), 156.5, 
155.6 (CO carbamate), 138.2 (Ph), 128.9-128.1 (Ph), 81.4 (C-4), 
80.37 (C-1), 77.5 (C-3), 75.1-72.4 (CH2Ph), 68.4 (OCH2), 67.1 (C-
6), 54.0 (CHNH), 53.3 (C-5), 52.9 (OCH3), 34.9 (C-2), 28.6 (CH3). 
ESIMS: m/z 593.3 [M + Na]+. ESI-HRMS Calcd for C30H38N2O9Na 
[M + Na]+ 593.2470, found 593.2456. 
(1R)-3,4-Di-O-benzyl-1-O-(Fmoc-l-Ser-OtBu)-5N,6O-
oxomethylidene-2-deoxynojirimycin (27). Column chromatography 
(1:6 → 1:4 EtOAc-cyclohexane). Yield: 21 mg (40%). Rf 0.4 (1:2 
EtOAc-cyclohexane). [α]D +36.1 (c 1.0 in DCM). 1H NMR (500 
MHz, CDCl3) δ 7.68 (d, 2 H, J = 7.8 Hz, Fmoc), 7.53 (d, 2 H, J = 
7.0 Hz, Fmoc), 7.32-7.18 (m, 14 H, Fmoc, Ph), 5.47 (d, 1 H, JNH,CH 
= 7.6 Hz, NH), 5.07 (m, 1 H, H-1), 4.87, 4.57 (2 d, 2 H, 2JH,H = 11.7 
Hz, CHPh), 4.58-4.56 (2 d, 1 H, 2JH,H = 11.6 Hz, CHPh), 4.37-4.27 
(m, 3 H, CHNH, CH2Fmoc), 4.22 (t, 1 H, J6a,6b = J5,6a = 8.4 Hz, H-
6a), 4.17 (t, 1 H, JH,H = 7.3 Hz, CHFmoc) 3.85-3.81 (m, 1 H, H-3), 
3.85-3.76 (m, 2 H, OCH2), 3.72-3.69 (m, 1 H, H-6b), 3.66-3.62 (m, 
1 H, H-5), 3.22 (t, 1 H, J3,4 = J4,5 = 8.8 Hz, H-4), 2.21 (m, 1 H, H-
2a), 1.56-1.51 (m, 1 H, H-2b), 1.42 (s, 9 H, CH3). 13C NMR (125.75 
MHz, CDCl3) δ 167.2 (CO ester), 156.5, 156.1 (CO carbamate), 
144.2, 141.6 (Fmoc), 138.2 (Ph), 132.6-127.4 (Ph), 125.4, 120.3 
(Fmoc), 83.0 (C-4), 81.5 (C-1), 80.6 (C-3), 75.1-72.5 (CH2Ph), 
68.9 (OCH2), 67.6 (CH2Fmoc), 67.2 (C-6), 55.0 (CHNH), 53.5 (C-
5), 47.5 (CHFmoc), 35.0 (C-2), 28.4 (CH3). ESIMS: m/z 757.3 [M 




(28). Column chromatography (1:6 EtOAc-toluene). Yield: 26 mg 
(57%). Rf 0.5 (1:2 EtOAc-toluene). [α]D +60.8 (c 1.0 in DCM). 1H 
NMR (500 MHz, CDCl3) δ 7.24-7.15 (m, 15 H, Ph), 5.10 (dd, 1 H, 
J1’,2’ = 3.7 Hz, J1’,2a’ = 1.8 Hz, H-1’), 4.92, 4.72 (2 d, 2 H, 2JH,H = 
10.6 Hz, CHPh), 4.86, 4.42 (2 d, 1 H, 2JH,H = 11.6 Hz, CHPh), 4.84, 
4.52 (2 d, 2 H, 2JH,H = 11.6 Hz, CHPh), 4.72,4.61 (d, 1 H, 2JH,H = 
12.8 Hz, CHPh), 4.60, 4.53 (d, 1 H, 2JH,H = 11.9 Hz, CHPh), 4.54 
(d, 1 H, J1,2 = 3.6 Hz, H-1), 3.92 (t, 1 H, J2,3 = J3,4 = 8.9 Hz, H-3), 
3.92 (t, 1 H, J5,6a = J6a,6b = 9.3 Hz, H-6a), 3.82-3.76 (m, 1 H, H-3’), 
3.66 (m, 1 H, H-5), 3.63-3.57 (m, 2 H, H-6a’, H-6b), 3.51 (dd, 1H, 
J5’,6b’ = 5.87 Hz, H-6b’), 3.48-3.44 (m, 2 H, H-2, H-5’), 3.39 (t, 1 
H, J4,5 = 9.4 Hz, H-4), 3.28 (s, 3 H, OMe), 3.17 (t, 1H, J4’,5’ = 9.1 
Hz, H-4’), 2.32 (ddd, 1 H J2a’,2b’ = 13.4 Hz, J2a’,3’ = 4.7 Hz, H-2a'), 
1.52 (ddd, 1 H,  H-2b’). 13C NMR (125.7 MHz, CDCl3) δ 156.5 
(CO), 138.1-137.9 (Ph), 128.5-127.2 (Ph), 98.3 (C-1), 82.5 (C-3), 
81.7 (C-4’), 80.4 (C-1’), 80.3 (C-2), 78.0 (C-4),77.3 (C-3’), 76.0-
72.3 (CH2Ph), 69.9 (C-5), 67.1 (C-6’), 66.9 (C-6), 55.5 (OMe), 53.3 
(C-5’), 35.0 (C-2’). ESIMS: m/z 838.4 [M + Na]+. ESI-HRMS 
Calcd for C49H53NNaO10 [M + Na]+ 838.3526, found 838.3562. 
(1R)-3,4-di-O-benzyl-1-O-(1,2-O-isopropylidene-5,6-O-(o-
xylylene)-α-D-glucofuranos-3-yl)-5N,6O-oxomethylidene-2-
deoxynojirimycin (29). Column chromatography (1:6 → 1:4 → 1:2 
EtOAc-cyclohexane). Yield: 17 mg (51%). Rf 0.7 (1:1 EtOAc-
cyclohexane). [α]D +12.0 (c 1.0 in DCM). 1H NMR (500 MHz, 
CDCl3) δ 7.39-7.22 (m, 14 H, Ph), 5.89 (d, 1 H, J1,2 = 3.8 Hz, H-1), 
5.22 (dd, 1 H, J1’,2’ = 4.0 Hz, J1’,2a’ = 1.8 Hz, H-1’), 4.94, 4.74 (2 d, 
2 H, 2JH,H = 12.5 Hz, CHPh), 4.92, 4.62 (2 d, 1 H, 2JH,H = 12.5 Hz, 
CHPh), 4.88, 4.60 (2 d, 1 H, 2JH,H = 12.0 Hz, CHPh), 4.55 (1 d, 1 
H, 2JH,H = 11.7 Hz, CHPh), 4.60 (d, 1 H, H-2), 4.43 (t, 1 H, J5’,6a’ = 
J6a’,6b’ = 7.0 Hz, H-6a'), 4.31 (dd, 1 H, J4,5 = 9.3 Hz, J3,4 = 3.4 Hz 
,H-4), 4.10 (d, 1 H, H-3), 4.04-3.95 (m, 1H, H-3’), 3.93-3.84 (m, 2 
H, H-5’, H-6a), 3.80 (dd, 1 H, J5’,6b’ = 10.8 Hz, J6a’,6b’ = 2.0 Hz, H-
6b’), 3.73-3.68 (m, 1H, H-5), 3.80 (dd, 1 H, J6a,6b = 11.0 Hz, J5,6b = 
4.5 Hz, H-6b), 3.34 (t, 1 H, J4’,5’ = 9.2 Hz, H-4’), 2.52 (ddd, 1 H 
J2a’,2b’ = 13.7 Hz, J2a’,3’ = 4.7 Hz, H-2a’), 1.66  (ddd, 1 H, H-2b’). 
13C NMR (125.7 MHz, CDCl3) δ 156.9 (CO), 138.6-136.4 (Ph), 
131.3-128.0 (Ph), 112.0 (C(CH3)2), 106.1 (C-1), 84.4 (C-2), 83.6 
(C-3), 82.0 (C-4’), 79.9 (C-1’), 79.6 (C-4), 78.2 (C-3’), 76.6 (C-5), 
75.0-72.5 (CH2Ph), 67.2 (C-6), 67.1 (C-6’), 53.2 (C-5’), 35.2 (C-
2’), 27.3, 26.7 (CH3). ESIMS: m/z 696.3 [M + Na]+. ESI-HRMS 







cin (31). Compounds 30 and 31 were obtained as a 2:1 mixture 
from 5 (20 mg, 57 mol) and the commercially available 1,2:5,6-
di-O-isopropylidene-α-D-glucofuranose 21 (22 mg, 86 mol) fol-
lowing the general O-glycosylation procedure. After 24 h the re-
sulting residue was purified by column chromatography (1:4 → 1:2 
EtOAc-toluene). Yield: 15 mg (43%). Rf 0.5 (1:2 EtOAc-toluene). 
ESIMS: m/z 634.2 [M + Na]+. ESI-HRMS Calcd for C33H41NNaO10 
[M + Na]+ 634.2623, found 634.2610.  
Data for 30: 1H NMR (500 MHz, CDCl3) δ 7.37-7.26 (m, 10 H, 
Ph), 5.83 (d, 1 H, J1,2 = 5.6 Hz, H-1), 5.39 (m, 1 H, H-1’), 4.96, 
4.65 (2 d, 2 H, 2JH,H = 11.5 Hz, CHPh), 4.70, 4.65 (2 d, 1 H, 2JH,H 
= 11.6 Hz, CHPh), 4.43 (d, 1 H, J1,2 = 3.40 Hz, H-2), 4.40 (t, 1 H, 
J5,’6a’ = J6a’,6b’ = 7.1 Hz, H-6a'), 4.33 (t, 1 H, H-6b’), 4.14 (d,  1 H, 
J3,4 = 2.9 Hz,  H-3),  4.11 (dd, 1 H, J6a, 6b = 5.8 Hz, J5,6a = 8.3 Hz, 
H-6a), 4.07 (dd, 1 H, J4,3 = 8.9 Hz, J4,5 = 3.0 Hz, H-4), 4.00 (dd, 1 
H, J5,6b = 4.9 Hz, H-6b), 3.98-3.91 (m, 1 H, H-3’), 3.98-3.91 (m, 1 
H, H-3), 3.82-3.77 (m, 1 H, H-5’), 3.34 (t, 1 H, J4’,5’ = 8.9 Hz, H-
4’), 2.40 (ddd, 1 H J2a’,2b’ = 13.5 Hz, J2a’,3’ = 4.8 Hz, H-2a'), 1.60 
(ddd, 1 H, H-2b’). 13C NMR (125.7 MHz, CDCl3) δ 155.9 (CO), 
138.1-137.8 (Ph), 128.6-127.7 (Ph), 112.22-109.4 (CH3), 105.4 (C-
1), 83.8 (C-2), 81.2 (C-4’), 80.4 (C-1’), 79.8 (C-4), 77.5 (C-3’), 
74.8-72.3 (CH2Ph), 72.3 (C-3), 67.7 (C-6), 67.0 (C-6’), 53.6 (C-5’), 
34.0 (C-2’). 
Data for 31:
 1H NMR (500 MHz, CDCl3) δ 7.37-7.26 (m, 10 H, 
Ph), 5.99 (d, 1 H, J1,2 = 3.6 Hz, H-1), 5.18 (dd, 1 H, H-1’), 4.96, 
4.65 (2 d, 2 H, 2JH,H = 11.5 Hz, CHPh), 4.70, 4.65 (2 d, 1 H, 2JH,H 
= 11.6 Hz, CHPh), 4.56 (d, 1 H, H-2), 4.40 (t, 1 H, J5’,6a’ = J6a’,6b’ = 
7.1 Hz, H-6a'), 4.33 (t, 1 H, H-6b’), 4.24 (dd, 1 H, J4,3 = 6.9 Hz, J4,5 
= 3.7 Hz, H-4), 4.19 (d, 1 H, H-3), 3.82-3.77 (m, 1 H, H-5’), 3.71-
3.66 (m, 2 H, H-5, H-6a), 3.58 (dd, 1 H, J5,6a = 10.1 Hz , J5,6a = 6.2 
Hz, H-6b), 3.29 (t, 1H, J4’,5’ = 8.9 Hz, H-4’), 2.40 (ddd, 1 H, J2a’,2b’ 
= 13.5 Hz, J2a’,3’ = 4.8 Hz, H-2a'), 1.60 (ddd, 1 H, H-2b’). 13C NMR 
(125.7 MHz, CDCl3) δ 156.4 (CO), 138.1-137.8 (Ph), 128.6-127.7 
(Ph), 112.22-109.4 (CH3), 106.4 (C-1), 84.0 (C-2), 81.4 (C-4’), 
80.5 (C-1’), 79.21 (C-4), 77.5 (C-3’), 75.0 (C-3), 74.8-72.3 
(CH2Ph), 71.0 (C-5), 68.3 (C-6’), 66.9 (C-6), 53.0 (C-5’), 34.9 (C-
2’). 
(1R)-3,4-Di-O-benzyl-1-O-(1-methyl α-D-galactopyranosyd-4-
yl)-5N,6O-oxomethylidene-2-deoxynojirimycin (33). Compound 
33 was obtained from glucal 5 (20 mg, 57 mol) and methyl 2,3,6-
tri-O-benzyl-α-D-galactopyranoside (22) (35 mg, 86 mol) follow-
ing the general procedure above described. After 24 h the resulting 
crude residue containing 32 and partially debenzoylated derivatives 
was concentrated and deprotected under Zemplén conditions (see 
General Methods). The resulting fully deacylated product was pu-
rified by column chromatography (1:2 EtOAc-cyclohexane → 9:1 
→ 4:1 EtOAc-MeOH) to give 33. Yield: 9 mg (29%, two steps). Rf 
0.6 (9:1 EtOAc-MeOH). [α]D +71.0 (c 0.65 in MeOH). 1H NMR 
(300 MHz, CD3OD) δ 7.40-7.27 (m, 10 H, Ph), 5.26 (dd, 1 H, J1’,2b’ 
= 4.0 Hz, J1’,2a’ = 1.7 Hz, H-1’), 4.91, 4.65 (2 d, 2 H, 2JH,H = 11.7 
Hz, CHPh), 4.73, 4.68 (2 d, 1 H, 2JH,H = 11.7 Hz, CHPh), 4.72 (d, 
1 H, J1,2 = 2.9 Hz, H-1), 4.42 (t, 1 H, J6a’,6b’ = J5’,6a’ = 8.3 Hz, H-6’), 
4.40-4.31 (m, 1 H, H-5’), 4.08-4.03 (m, 2 H, H-3, H-3’), 3.96-3.91 
(t, 1 H, J5’,6b’ = J6a’,6b’ = 7.8 Hz, H-6b’), 3.87 (t, 1 H, J5,6a = J5,6b = 
6.9 Hz, H-5), 3.84-3.75 (m, 4 H, H-2, H-4, H-6), 3.44 (t, 2 H, J3’,4’ 
= J4’,5’ = 9.6 Hz, H-4’), 3.41 (s, 3 H, OMe), 2.48 (ddd, 1 H J2a’,2b’ = 
13.4 Hz, J2a’,3’ = 4.7 Hz, H-2a'), 1.64 (ddd, 1 H, H-2b’). 13C NMR 
(125.1 MHz, CDCl3) δ 156.9 (CO), 140.7-140.6 (Ph), 130.3-129.9 
(Ph), 102.4 (C-1), 84.1 (C-4’), 82.7 (C-1’), 79.5, 79.3 (C-3’, C-3), 
76.2, 73.9 (CH2Ph), 73.2 (C-5), 71.4 (C-2), 71.4 (C-4), 69.6 (C-6’), 
62.7 (C-6), 56.7 (OMe), 55.4 (C-5’), 36.7 (C-2’). ESIMS: m/z 568.2 
[M + Na]+. ESI-HRMS Calcd for C28H35NNaO10 [M + Na]+ 
568.2153, found 568.2146. 
(1R)-3,4-Di-O-benzyl-1-octylthio-5N,6O-oxomethylidene-2-
deoxynojirimycin (34). Column chromatography (1:3 EtOAc-
toluene). Yield: 24 mg (85%). Rf 0.6 (1:2 EtOAc-toluene). [α]D 
+63.7 (c 0.6 in DCM). 1H NMR (500 MHz, CDCl3) δ 7.41-7.30 (m, 
10 H, Ph), 5.30 (dd, 1 H, J1,2b = 4.9 Hz, J1,2a = 1.7 Hz, H-1), 4.98, 
4.68 (2 d, 2 H, 2JH,H = 11.7 Hz, CHPh), 4.70, 4.65 (2 d, 1 H, 2JH,H 
= 11.5 Hz, CHPh), 4.40 (t, 1 H, J6a,6b = J5,6a = 8.6 Hz, H-6a), 4.05-
3.91 (m, 2 H, H-3, H-5), 3.84 (dd, 1 H, J5,6b = 6.7 Hz, H-6b), 3.30 
(t, 1 H, J3,4 = J4,5 = 8.9 Hz, H-4), 2.66-2.57 (m, 1 H, SCH2), 2.52-
2.43 (m, 1 H, SCH2), 2.30 (ddd, 1 H, J2a,2b = 13.6 Hz, J2a,3 = 4.6 Hz, 
H-2a), 1.91 (ddd, 1 H, J2b,3 = 11.2 Hz, H-2b), 1.69-1.51 (m, 2 H, 
CH2), 1.36-1.28 (m, 7 H, CH2), 0.90 (t, 3 H, 3JH,H = 6.5 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3) δ 156.3 (CO), 138.3-138.2 (Ph), 
129.0-128.2 (Ph), 82.0 (C-4), 78.5 (C-3), 75.1, 72.5 (CH2Ph), 67.0 
(C-6), 55.3 (C-1), 52.9 (C-5), 35.4 (C-2), 35.4 (SCH2), 32.3-28.9 
(CH2), 23.0 (CH3). ESIMS: m/z 520.3 [M + Na]+. ESI-HRMS 
Calcd for C29H39NO4NaS [M + Na]+ 520.2492, found 520.2487. 
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